Condition: Endometrial Cancer · Sponsor: Alessandro Santin
The purpose of this study is to evaluate the activity and safety profile of mirvetuximab soravtansine (IMGN853) in patients with type II endometrial cancers that overexpress folate receptor alpha (FRα).
This description comes directly from the study's public registry record.
Alessandro D. Santin, M.D. · 203-737-4450 · alessandro.santin@yale.edu
Lisa Baker, R.N. · 203-785-6398 · lisa.baker@yale.edu
Always discuss trial participation with your own doctor first.
| Smilow Cancer Hospital at Yale New Haven | New Haven, Connecticut, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03832361